These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 171574)

  • 61. Hyperlipidemia in primary gout.
    Yü TF; Dorph DJ; Smith H
    Semin Arthritis Rheum; 1978 May; 7(4):233-44. PubMed ID: 347582
    [No Abstract]   [Full Text] [Related]  

  • 62. Ionophoretic activity of hypoglycemic sulfonylureas.
    Couturier E; Malaisse WJ
    Arch Int Pharmacodyn Ther; 1980 Jun; 245(2):323-34. PubMed ID: 6250506
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Halofenate: effectiveness of two dosage forms and two dose schedules.
    Hutchison JC; Wilkinson WH
    Atherosclerosis; 1974; 19(3):417-28. PubMed ID: 4133379
    [No Abstract]   [Full Text] [Related]  

  • 64. Studies of the uricosuric action of the hypolipidemic drug halofenate.
    Ravenscroft PJ; Sands JM; Emmerson BT
    Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262
    [No Abstract]   [Full Text] [Related]  

  • 65. Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin.
    Vesell ES; Passananti GT
    Pharmacology; 1975; 13(2):112-27. PubMed ID: 49900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oral hypoglycemic agent update.
    Krall LP; Chabot VA
    Med Clin North Am; 1978 Jul; 62(4):681-94. PubMed ID: 98675
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of halofenate on the serum binding of phenytoin.
    Karch FE; Wardell WM; Dambly M; Gringeri A
    Br J Clin Pharmacol; 1977 Oct; 4(5):625-6. PubMed ID: 911611
    [No Abstract]   [Full Text] [Related]  

  • 68. Influence of hypoglycemic agents on blood lipids and body weight in ketoacidosis-resistant diabetics.
    Gershberg H; Javier Z; Hulse M; Hecht A
    Ann N Y Acad Sci; 1968 Mar; 148(3):914-24. PubMed ID: 4968572
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparison of the effects of clofibrate and halofenate (MK-185) in isolated rat hepatocytes.
    Homcy CJ; Margolis S
    Atherosclerosis; 1974; 19(3):381-91. PubMed ID: 4828566
    [No Abstract]   [Full Text] [Related]  

  • 70. Assessment of the need for continued oral therapy in diabetics.
    Tomkins AM; Bloom A
    Br Med J; 1972 Mar; 1(5801):649-51. PubMed ID: 5015290
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of halofenate and clofibrate on growth and lipid synthesis in Saccharomyces cerevisiae.
    Greenspan MD; Germershausen JI
    J Bacteriol; 1973 Feb; 113(2):847-55. PubMed ID: 4570609
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of halofenate on exercise performance in coronary heart disease.
    Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
    Clin Pharmacol Ther; 1973; 14(3):366-70. PubMed ID: 4698564
    [No Abstract]   [Full Text] [Related]  

  • 73. Effects of sulfonylurea compounds on hyperlipemia and hypercholesteremia in patients with minimal impairment of glucose tolerance.
    SHIPP JC; MUNROE JF
    Diabetes; 1962; 11(Suppl)():69-73. PubMed ID: 13977373
    [No Abstract]   [Full Text] [Related]  

  • 74. [Comparative evaluation of the hypoglycemic activity of glyoxamide and tolbutamide in normal states and in experimental diabetes].
    Khaleeva LD; Timasheva IN; Voronina LN; Petiunin PA; Chernykh VP
    Probl Endokrinol (Mosk); 1981; 27(4):46-8. PubMed ID: 7291151
    [No Abstract]   [Full Text] [Related]  

  • 75. [Therapeutic of acetiromate on hyperlipidemia--comparison with clofibrate using a double-blind method].
    Nakano Y; Fukui I; Niiho S; Kuki H; Takahata J
    Nihon Rinsho; 1974 Jul; 32(7):2526-51. PubMed ID: 4612204
    [No Abstract]   [Full Text] [Related]  

  • 76. High-density-lipoprotein and maturity-onset diabetes.
    Stalenhoef AF; Demacker PN; Lutterman JA; Van't Laar A
    Lancet; 1978 Feb; 1(8059):325. PubMed ID: 75356
    [No Abstract]   [Full Text] [Related]  

  • 77. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
    Daubresse JC; Daigneux D; Bruwier M; Luyckx A; Lefebvre PJ
    Br J Clin Pharmacol; 1979 Jun; 7(6):599-603. PubMed ID: 380614
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
    Morgan JP; Bianchine JR; Hsu TH; Margolis S
    Clin Pharmacol Ther; 1971; 12(3):517-24. PubMed ID: 4936037
    [No Abstract]   [Full Text] [Related]  

  • 79. Clinical and experimental findings after five years' treatment of diabetes with sulfonylureas.
    MEHNERT H
    Diabetes; 1962; 11(Suppl)():80-4. PubMed ID: 13934500
    [No Abstract]   [Full Text] [Related]  

  • 80. The effect of tolbutamide on the diabetic fatty liver.
    Beringer A; Hrabal I; Irsigler K; Thaler H
    Ger Med Mon; 1968 Dec; 13(12):595-8. PubMed ID: 4898499
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.